Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025The OncologistOpen Access

Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAndrea BlascoSLSara López‐TarruellaAUAnder Urruticoechea

Discussion

Loading...

Member takes

Overview

Analysis reveals surrogate endpoints correlate well with overall survival in breast cancer, suggesting careful endpoint selection based on subtype.

Key Points

  • Invasive disease-free survival and invasive BC-free survival show strong correlation with overall survival, indicating their effectiveness as surrogate endpoints.
  • The study analyzed data from 8 phase III randomized adjuvant chemotherapy trials to evaluate the use of intermediate endpoints as predictors of overall survival.
  • Surrogacy analysis demonstrated R2 values above 0.7 for certain endpoints, showcasing their potential reliability in treatment outcome predictions.
  • The findings suggest that selecting the primary endpoint should consider breast cancer subtype to improve the evaluation of adjuvant interventions.

Cite This Study

Blasco et al. (2025) studied this question.

synapsesocial.com/papers/68af76bf7567bf4f94fefd49https://doi.org/10.1093/oncolo/oyaf263
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer2025
  2. 2Surrogate endpoints for overall survival in advanced hepatocelluar carcinoma in the era of immunotherapy: a trial level meta-analysis2025
  3. 3Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer2025
  4. 4Real‐world clinical outcomes of patients with high‐risk endometrial cancer or endometrial carcinosarcoma in England: A retrospective cohort study2025
  5. 5Informative Censoring in CDK4/6 Inhibitor Adjuvant Therapy for Early Breast Cancer: A Sensitivity Analysis of Invasive Disease-Free Survival in the monarchE Trial2025